医学
相(物质)
疾病
癌症研究
临床试验
药理学
临床研究阶段
内科学
免疫系统
免疫学
作者
Diamant Thaçi,Vivian Laquer,Charles Lynde,Adam Reich,Weily Soong,Margitta Worm,Petra Arlert,Allan Blemings,Thomas Litman,Britta C. Martel,Martin Olesen,Ole E. Sørensen,Melinda Gooderham
标识
DOI:10.1016/j.jaci.2025.08.034
摘要
This proof-of-concept study demonstrates that targeting the IL-22 pathway with temtokibart is clinically effective with a favorable safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI